The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2020-04-01 11:17:162020-04-11 20:44:49U.S. FDA moves to remove all versions of heartburn drug Zantac from market
